150 related articles for article (PubMed ID: 22471520)
1. Protein expression changes in ovarian cancer during the transition from benign to malignant.
Waldemarson S; Krogh M; Alaiya A; Kirik U; Schedvins K; Auer G; Hansson KM; Ossola R; Aebersold R; Lee H; Malmström J; James P
J Proteome Res; 2012 May; 11(5):2876-89. PubMed ID: 22471520
[TBL] [Abstract][Full Text] [Related]
2. Comparative proteomics of ovarian epithelial tumors.
An HJ; Kim DS; Park YK; Kim SK; Choi YP; Kang S; Ding B; Cho NH
J Proteome Res; 2006 May; 5(5):1082-90. PubMed ID: 16674097
[TBL] [Abstract][Full Text] [Related]
3. Increased WD-repeat containing protein 1 in interstitial fluid from ovarian carcinomas shown by comparative proteomic analysis of malignant and healthy gynecological tissue.
Haslene-Hox H; Oveland E; Woie K; Salvesen HB; Wiig H; Tenstad O
Biochim Biophys Acta; 2013 Nov; 1834(11):2347-59. PubMed ID: 23707566
[TBL] [Abstract][Full Text] [Related]
4. Discovery of serum biomarkers implicated in the onset and progression of serous ovarian cancer in a rat model using iTRAQ technique.
Huang Y; Zhang X; Jiang W; Wang Y; Jin H; Liu X; Xu C
Eur J Obstet Gynecol Reprod Biol; 2012 Nov; 165(1):96-103. PubMed ID: 22818854
[TBL] [Abstract][Full Text] [Related]
5. A proteomic signature of ovarian cancer tumor fluid identified by highthroughput and verified by targeted proteomics.
Poersch A; Grassi ML; Carvalho VP; Lanfredi GP; Palma CS; Greene LJ; de Sousa CB; Carrara HHA; Candido Dos Reis FJ; Faça VM
J Proteomics; 2016 Aug; 145():226-236. PubMed ID: 27222041
[TBL] [Abstract][Full Text] [Related]
6. Profiling signatures of ovarian cancer tumour suppression using 2D-DIGE and 2D-LC-MS/MS with tandem mass tagging.
Sinclair J; Metodieva G; Dafou D; Gayther SA; Timms JF
J Proteomics; 2011 Apr; 74(4):451-65. PubMed ID: 21237297
[TBL] [Abstract][Full Text] [Related]
7. In-depth proteomic analyses of ovarian cancer cell line exosomes reveals differential enrichment of functional categories compared to the NCI 60 proteome.
Sinha A; Ignatchenko V; Ignatchenko A; Mejia-Guerrero S; Kislinger T
Biochem Biophys Res Commun; 2014 Mar; 445(4):694-701. PubMed ID: 24434149
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive proteome analysis of ovarian cancers using liquid phase separation, mass mapping and tandem mass spectrometry: a strategy for identification of candidate cancer biomarkers.
Wang H; Kachman MT; Schwartz DR; Cho KR; Lubman DM
Proteomics; 2004 Aug; 4(8):2476-95. PubMed ID: 15274142
[TBL] [Abstract][Full Text] [Related]
9. Early inflammatory response in epithelial ovarian tumor cyst fluids.
Kristjánsdóttir B; Partheen K; Fung ET; Yip C; Levan K; Sundfeldt K
Cancer Med; 2014 Oct; 3(5):1302-12. PubMed ID: 24947406
[TBL] [Abstract][Full Text] [Related]
10. Variation in cell signaling protein expression may introduce sampling bias in primary epithelial ovarian cancer.
Mittermeyer G; Malinowsky K; Beese C; Höfler H; Schmalfeldt B; Becker KF; Avril S
PLoS One; 2013; 8(10):e77825. PubMed ID: 24204986
[TBL] [Abstract][Full Text] [Related]
11. Proteome profiling of human epithelial ovarian cancer cell line TOV-112D.
Gagné JP; Gagné P; Hunter JM; Bonicalzi ME; Lemay JF; Kelly I; Le Page C; Provencher D; Mes-Masson AM; Droit A; Bourgais D; Poirier GG
Mol Cell Biochem; 2005 Jul; 275(1-2):25-55. PubMed ID: 16335783
[TBL] [Abstract][Full Text] [Related]
12. High GOLPH3 expression is associated with a more aggressive behavior of epithelial ovarian carcinoma.
Ma Y; Ren Y; Zhang X; Lin L; Liu Y; Rong F; Wen W; Li F
Virchows Arch; 2014 Apr; 464(4):443-52. PubMed ID: 24458516
[TBL] [Abstract][Full Text] [Related]
13. Human epithelial-type ovarian tumour marker beta-2-microglobulin is regulated by the TGF-β signaling pathway.
Sun W; Gui L; Zuo X; Zhang L; Zhou D; Duan X; Ren W; Xu G
J Transl Med; 2016 Mar; 14():75. PubMed ID: 26983758
[TBL] [Abstract][Full Text] [Related]
14. Depletion of Dicer promotes epithelial ovarian cancer progression by elevating PDIA3 expression.
Zhu Y; Cai L; Guo J; Chen N; Yi X; Zhao Y; Cai J; Wang Z
Tumour Biol; 2016 Oct; 37(10):14009-14023. PubMed ID: 27492604
[TBL] [Abstract][Full Text] [Related]
15. Identification and validation of differentially expressed proteins in epithelial ovarian cancers using quantitative proteomics.
Qu H; Chen Y; Cao G; Liu C; Xu J; Deng H; Zhang Z
Oncotarget; 2016 Dec; 7(50):83187-83199. PubMed ID: 27825122
[TBL] [Abstract][Full Text] [Related]
16. Molecular diagnosis in type I epithelial ovarian cancer.
Sadłecki P; Walentowicz-Sadłecka M; Grabiec M
Ginekol Pol; 2017; 88(12):692-697. PubMed ID: 29303228
[TBL] [Abstract][Full Text] [Related]
17. Discovery of serum biomarkers of ovarian cancer using complementary proteomic profiling strategies.
Timms JF; Arslan-Low E; Kabir M; Worthington J; Camuzeaux S; Sinclair J; Szaub J; Afrough B; Podust VN; Fourkala EO; Cubizolles M; Kronenberg F; Fung ET; Gentry-Maharaj A; Menon U; Jacobs I
Proteomics Clin Appl; 2014 Dec; 8(11-12):982-93. PubMed ID: 25290619
[TBL] [Abstract][Full Text] [Related]
18. Quantitative proteome analysis of ovarian cancer tissues using a iTRAQ approach.
Wang LN; Tong SW; Hu HD; Ye F; Li SL; Ren H; Zhang DZ; Xiang R; Yang YX
J Cell Biochem; 2012 Dec; 113(12):3762-72. PubMed ID: 22807371
[TBL] [Abstract][Full Text] [Related]
19. Defective expression of Protein 4.1N is correlated to tumor progression, aggressive behaviors and chemotherapy resistance in epithelial ovarian cancer.
Xi C; Ren C; Hu A; Lin J; Yao Q; Wang Y; Gao Z; An X; Liu C
Gynecol Oncol; 2013 Dec; 131(3):764-71. PubMed ID: 23994105
[TBL] [Abstract][Full Text] [Related]
20. Fibrillar type I collagen matrices enhance metastasis/invasion of ovarian epithelial cancer via β1 integrin and PTEN signals.
Shen Y; Shen R; Ge L; Zhu Q; Li F
Int J Gynecol Cancer; 2012 Oct; 22(8):1316-24. PubMed ID: 23013730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
